Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 509-521

  Naesens, Maarten ^a   Kuypers, Dirk R J ^a   Streit, Frank ^a   Armstrong, Victor W ^a   Oellerich, Michael ^a   Verbeke, Kristin ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCOCORTICOID; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID 7 O GLUCURONIDE; MYCOPHENOLIC ACID ACYL GLUCURONIDE; PREGNANE X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; ENZYME ACTIVITY; GRAFT RECIPIENT; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY ALLOGRAFT; KIDNEY CLEARANCE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN TRANSPORT; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HOMOZYGOTE; HUMANS; KIDNEY TRANSPLANTATION; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RIFAMPIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750942519     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.08.002     Document Type: Article

References (56)

1. Srinivas T.R., Kaplan B., Schold J.D., and Meier-Kriesche H.U. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 80 (2005) S211-S220
2. Appel G.B., Radhakrishnan J., and Ginzler E. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 80 (2005) S265-S271
3. Bullingham R., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 64 (1998) 429-455
4. Mackenzie P.I. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22 (2000) 10-13
5. Shipkova M., Strassburg C.P., Braun F., Streit F., Grone H.-J., Armstrong V.W., et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132 (2001) 1027-1034
6. Basu N.K., Kole L., Kubota S., and Owens I.S. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32 (2004) 768-773
7. Picard N., Ratanasavanh D., Premaud A., Le Meur Y., and Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33 (2005) 139-146
8. Wieland E., Shipkova M., Schellhaas U., Schutz E., Niedmann P.D., Armstrong V.W., et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. Clin Biochem 33 (2000) 107-113
9. Kuypers D.R.J., Vanrenterghem Y., Squifflet J., Mourad M., Abramowicz D., Oellerich M., et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25 (2003) 609-622
10. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25 (2003) 1-16
11. Kobayashi M., Saitoh H., Kobayashi M., Tadano K., Takahashi Y., and Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309 (2004) 1029-1035
12. Hesselink D.A., van Hest R.M., Mathot R.A.A., Bonthuis F., Weimar W., de Bruin R.W.F., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987-995
13. Westley I.S., Brogan L.R., Morris R.G., Evans A.M., and Sallustio B.C. Role of Mrp2 in the hepatic disposition of mycophenolic acid: effect of cyclosporin. Drug Metab Dispos 34 (2006) 261-266
14. Bullingham R., Monroe S., Nicholls A., and Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36 (1996) 315-324
15. Shaw L.M., Korecka M., Venkataramanan R., Goldberg L., Bloom R., and Brayman K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3 (2003) 534-542
16. Schaub T.P., Kartenbeck J., Konig J., Spring H., Dorsam J., Staehler G., et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10 (1999) 1159-1169
17. Kuypers D.R.J., Claes K., Evenepoel P., Maes B., Coosemans W., Pirenne J., et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 43 (2003) 866-880
18. Shaw L.M., Mick R., Nowak I., Korecka M., and Brayman K.L. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 38 (1998) 268-275
19. van Hest R., Mathot R., Pescovitz M.D., Gordon R., Mamelok R., and van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17 (2006) 871-880
20. Weber L.T., Shipkova M., Armstrong V.W., Wagner N., Schutz E., Mehls O., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13 (2002) 759-768
21. Parker G., Bullingham R., Kamm B., and Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 36 (1996) 332-344
22. Kuypers D., Naesens M., Vermeire S., and Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78 (2005) 351-361
23. van Gelder T., Le Meur Y., Shaw L.M., Oellerich M., DeNofrio D., Holt C., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
24. Zucker K., Rosen A., Tsaroucha A., de Faria L., Roth D., Ciancio G., et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 5 (1997) 225-232
25. van Gelder T., Klupp J., Barten M.J., Christians U., and Morris R.E. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
26. Naderer O.J., Dupuis R.E., Heinzen E.L., Wiwattanawongsa K., Johnson M.W., and Smith P.C. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 45 (2005) 219-226
27. Morii M., Ueno K., Ogawa A., Kato R., Yoshimura H., Wada K., et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 68 (2000) 613-616
28. Bullingham R., Shah J., Goldblum R., and Shiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 41 (1996) 513-516
29. Gimenez F., Foeillet E., Bourdon O., Weller S., Garret C., Bidault R., et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet 43 (2004) 685-692
30. Kuypers D., Verleden G., Naesens M., and Vanrenterghem Y. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 78 (2005) 81-88
31. Williams J.A., Hyland R., Jones B.C., Smith D.A., Hurst S., Goosen T.C., et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab Dispos 32 (2004) 1201-1208
32. Kiang T.K.L., Ensom M.H.H., and Chang T.K.H. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106 (2005) 97-132
33. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
34. Meyer zu Schwabedissen H.E., Jedlitschky G., Gratz M., Haenisch S., Linnemann K., Fusch C., et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 33 (2005) 896-904
35. Haenisch S., Zimmermann U., Dazert E., Wruck C.J., Dazert P., Siegmund S., et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J (2006) In press
36. Streit F., Shipkova M., Armstrong V.W., and Oellerich M. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem 50 (2004) 152-159
37. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299 (2001) 849-857
38. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P.S., Negishi Y., Bottroff B.S., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A 100 (2003) 4150-4155
39. Toide K., Takahashi Y., Yamazaki H., Terauchi Y., Fujii T., Parkinson A., et al. Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos 30 (2002) 613-615
40. Gallicano K.D., Sahai J., Shukla V.K., Seguin I., Pakuts A., Kwok D., et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 48 (1999) 168-179
41. Barbier O., Turgeon D., Girard C., Green M.D., Tephly T.R., Hum D.W., et al. 3'-Azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28 (2000) 497-502
42. Soars M.G., Petullo D.M., Eckstein J.A., Kasper S.C., and Wrighton S.A. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32 (2004) 140-148
43. Schmidt L.E., Rasmussen A., Norrelykke M.R., Poulsen H.E., and Hansen B.A. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl 7 (2001) 739-742
44. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (2002) 2908-2915
45. Fromm M.F., Kauffmann H.M., Fritz P., Burk O., Kroemer H.K., Warzok R.W., et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157 (2000) 1575-1580
46. Oswald S., Haenisch S., Fricke C., Sudhop T., Remmler C., Giessmann T., et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79 (2006) 206-217
47. Kauffmann H.M., Keppler D., Gant T.W., and Schrenk D. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol 72 (1998) 763-768
48. Marschall H.U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129 (2005) 476-485
49. Cui Y., Konig J., and Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60 (2001) 934-943
50. Lau Y.Y., Okochi H., Huang Y., and Benet L.Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316 (2006) 762-771
51. Bidstrup T.B., Stilling N., Damkier P., Scharling B., Thomsen M., and Brosen K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60 (2004) 109-114
52. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92 (1998) 73-82
53. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104 (1999) 147-153
54. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68 (2000) 345-355
55. Hamman M.A., Bruce M.A., Haehner-Daniels B.D., and Hall S.D. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69 (2001) 114-121
56. Bernard O., and Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32 (2004) 775-778